Montanova Capital LLC raised its stake in InflaRx N.V. (NASDAQ:IFRX - Free Report) by 189.1% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,933,910 shares of the company's stock after purchasing an additional 15,000,000 shares during the period. InflaRx comprises 0.9% of Montanova Capital LLC's investment portfolio, making the stock its 29th biggest position. Montanova Capital LLC owned approximately 15.57% of InflaRx worth $51,372,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other hedge funds and other institutional investors have also made changes to their positions in the stock. Suvretta Capital Management LLC grew its position in shares of InflaRx by 22.4% during the fourth quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company's stock worth $8,013,000 after buying an additional 1,450,000 shares in the last quarter. Spruce Street Capital LP purchased a new position in InflaRx in the second quarter worth approximately $11,988,924. 683 Capital Management LLC lifted its stake in InflaRx by 47.3% in the fourth quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company's stock worth $3,348,000 after acquiring an additional 1,065,000 shares during the last quarter. ADAR1 Capital Management LLC acquired a new position in InflaRx during the 2nd quarter worth approximately $6,720,000. Finally, Bank of America Corp DE purchased a new stake in shares of InflaRx in the 3rd quarter valued at approximately $3,316,000. Hedge funds and other institutional investors own 42.39% of the company's stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently weighed in on IFRX shares. Weiss Ratings restated a "sell (d-)" rating on shares of InflaRx in a report on Wednesday, June 24th. HC Wainwright increased their target price on InflaRx from $6.00 to $8.00 and gave the company a "buy" rating in a report on Monday, May 11th. Raymond James Financial upgraded InflaRx from an "outperform" rating to a "strong-buy" rating and raised their price target for the company from $7.00 to $9.00 in a research note on Wednesday, May 13th. Wall Street Zen raised InflaRx from a "sell" rating to a "hold" rating in a report on Saturday, May 9th. Finally, Zacks Research cut InflaRx from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 25th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, InflaRx currently has an average rating of "Moderate Buy" and an average target price of $7.33.
Get Our Latest Stock Analysis on IFRX
InflaRx Price Performance
NASDAQ IFRX opened at $2.13 on Tuesday. The firm's fifty day moving average price is $1.99 and its 200 day moving average price is $1.67. The company has a market capitalization of $313.90 million, a price-to-earnings ratio of -3.67 and a beta of 2.48. InflaRx N.V. has a 12 month low of $0.80 and a 12 month high of $2.95.
InflaRx (NASDAQ:IFRX - Get Free Report) last released its quarterly earnings data on Friday, August 7th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). As a group, sell-side analysts forecast that InflaRx N.V. will post -0.31 earnings per share for the current year.
About InflaRx
(
Free Report)
InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company's lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.
Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.
Recommended Stories
Want to see what other hedge funds are holding IFRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for InflaRx N.V. (NASDAQ:IFRX - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider InflaRx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InflaRx wasn't on the list.
While InflaRx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
